STRS Ohio’s Lyell Immunopharma LYEL Stock Holding History

STRS Ohio’s Portfolio LYEL Stock Details LYEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-255	Closed	-$2.74K	–	2260
2025 Q1	$2.74K	Hold	255	–	–	﹤0.01%	1907
2024 Q4	$3.26K	Hold	255	–	–	﹤0.01%	1868
2024 Q3	$7.04K	Hold	255	–	–	﹤0.01%	1942
2024 Q2	$7.39K	Hold	255	–	–	﹤0.01%	1927
2024 Q1	$11K	Sell	255 -15	-6%	-$642	﹤0.01%	1876
2023 Q4	$10K	Hold	270	–	–	﹤0.01%	1874
2023 Q3	$7K	Hold	270	–	–	﹤0.01%	1912
2023 Q2	$17K	Hold	270	–	–	﹤0.01%	1894
2023 Q1	$12K	Hold	270	–	–	﹤0.01%	1892
2022 Q4	$18K	Hold	270	–	–	﹤0.01%	1893
2022 Q3	$39K	Hold	270	–	–	﹤0.01%	1855
2022 Q2	$35K	Hold	270	–	–	﹤0.01%	1912
2022 Q1	$27K	Hold	270	–	–	﹤0.01%	2020
2021 Q4	$41K	Hold	270	–	–	﹤0.01%	2035
2021 Q3	$79K	Buy	+270	New	+$80.9K	﹤0.01%	1984

Other funds holding LYEL

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return

OPL

Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCMV

Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

STRS Ohio's LYEL Position: Q2 2025 in Review

STRS Ohio sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 255 shares — an estimated $2.74K sold.

STRS Ohio first reported a position in LYEL in Q3 2021 and held it in 15 quarters. The position peaked at $79K in Q3 2021. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

STRS Ohio reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
STRS Ohio sold 255 Lyell Immunopharma shares in Q2 2025, an estimated $2.74K.
STRS Ohio first reported a position in Lyell Immunopharma in Q3 2021 and held it in 15 quarters.
STRS Ohio's Lyell Immunopharma position peaked at $79K in Q3 2021.
69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on STRS Ohio's 13F filing for Q2 2025, filed 4 Aug 2025.